HCW Biologics Inc. reported financial results for the quarter ended June 30, 2026, including a net loss of $5.2 million and revenues of $135,568. The company raised approximately $5.6 million in equity financings through private placements in May and July 2026, with participation from executives and directors. HCW Biologics announced preliminary positive data for its lead autoimmune candidate HCW9302 in alopecia areata patients and initiated a Type B meeting with the FDA regarding its T-cell engager candidate HCW11-018b. Additionally, the company re-acquired ex vivo rights to commercial-ready molecules from AlloTera Therapeutics and completed a one-for-six reverse stock split on June 30, 2026. The filing also notes regained compliance with Nasdaq listing rules. HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia.
